The expanded partnership adds Denmark, Finland, Norway and Sweden to GENESIS Pharma’s existing network of thirteen Southeast European markets. It grants rights for the commercialization of Alnylam’s RNAi therapeutics for serious ca... Read more
Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, announced the successful dosing of the first patients across multiple clinical sites with ANOC-001, a ... Read more
New registry will generate robust real-world evidence on disease burden, treatment patterns and long-term effectiveness of newly approved and emerging therapies Thermo Fisher Scientific, the world leader in serving science, announced the lau... Read more
Move reinforces Axplora’s integrated API supply model, expands critical manufacturing capabilities in India and enables Farmabios to sharpen focus on Steroids and HPAPI leadership Axplora, a global leader in the manufacturi... Read more
Clinical Trial approval for TCX-001 is another significant development milestone for T-CURX and marks the transition of T-CURX from a pre-clinical to a clinical-stage biotech company TCX-001 targeting Siglec-6 is a first-in-class autologous, non... Read more
Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing New Money Facility, maturing in May 2027 Eliminates near‑term debt maturities and strengthens b... Read more
Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income from operations increased to EUR 241 million Adjusted EBITA margin increased 40 basis points t... Read more
AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteina... Read more
LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic ... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
